Pharmacology Watch
RSSArticles
-
Possible Link Between Acetaminophen Use During Pregnancy and Later ADHD Development
A recent study showed that long-term maternal use of acetaminophen during pregnancy was associated substantially with ADHD, even after adjusting for indications of use, familial risk of ADHD, and other potential confounders. However, given that paternal use of acetaminophen also was associated with ADHD, the causal role of acetaminophen can be questioned.
-
FDA Actions
In this section: The FDA unveils new adverse events dashboard tool, announces intent to hasten generic drug approvals, greenlights a generic drug to treat multiple sclerosis, greenlights biosimilar to treat multiple types of cancers, gives go ahead to leukemia treatment, and approves updated herpes zoster vaccine.
-
Possible Adverse Cardiovascular Events Slow Osteoporosis Drug Approval Process
Romosozumab appears to outperform alendronate for fracture prevention in women with osteoporosis, but an increase in cardiovascular adverse events has derailed FDA approval.
-
Comparing Two Important Hormone Therapy Treatments
New data from the Women’s Health Initiative may be reassuring for women on postmenopausal hormone therapy. The data show no higher mortality rate with hormone use after long-term follow-up.
-
What Is the Appropriate Length of Opioid Prescriptions After Routine Surgeries?
Postsurgical opioid prescriptions often lead to extra pills stored in unsecured locations in homes. This represents a potential source for non-medical opioid use and associated morbidity and mortality for patients and their families.
-
FDA Actions
In this section: The agency approves fixed-dose combination hepatitis C treatment, greenlights first U.S. gene therapy, and approves new urinary tract infection drug.
-
Treating Pain and PTSD with Cannabis
There is insufficient evidence today to draw conclusions about the benefits and harms of plant-based cannabis preparations in patients with PTSD.
-
Canagliflozin Reduces Cardiovascular Events in Diabetic Patients
Canagliflozin resulted in a lower risk of cardiovascular disease in type 2 diabetics who were at high cardiovascular risk. However, there was a higher risk of amputation, which is a new finding.
-
New Data Show Liraglutide Improves Renal Outcomes in Type 2 Diabetes Patients
In a recent trial, when added to usual care for type 2 diabetes, investigators concluded that liraglutide resulted in lower rates of the development and progression of diabetic kidney disease than placebo.
-
FDA Actions
In this section: FDA approves new treatments for breast cancer and hepatitis C.